• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to project page

2007 Fiscal Year Annual Research Report

がん治療ペプチドワクチンの基礎的研究

Research Project

Project/Area Number 17016074
Research InstitutionKurume University

Principal Investigator

伊東 恭悟  Kurume University, 医学部, 教授 (50125499)

Keywordsがん治療ペプチドワクチン / キラーT細胞 / ペプチド抗体 / 上皮性癌 / 単クローン抗体
Research Abstract

がん治療ペプチドワクチン開発の基盤的研究をテーマに多くの研究成果を発表してきた。主な成果を以下に示す。
(1)がん関連抗原由来ペプチドのうち細胞障害性T細胞(cytotoxic T lymhocytes,CTL)を誘導するペプチドを同定した(HLA-A24拘束性:Harada他.,Oncol.Rep.等、HLA-A2拘束性:Itoh他.,Oncol.Rep.、HLA-A3スーパーファミリー拘束性:Matsueda他.,J Immunother,2007等)。(2)C型肝炎ウイルス由来ペプチドよりHLA-拘束性CTLを誘導するペプチドを同定した(Takao他、Hep.Res,2007)。(3)ペプチド特異的IgG抗体測定がペプチドワクチンの予後予測バイオマーカーとして有用であることを、すい臓がん(Yanagimoto他、Can.Sci,2007)、胃・大腸がん(Sato他、Can.Sci,2007)、前立腺がん(Noguchi他、OncolRes,2007)において明らかにした。(4)テーラーメイドペプチドワクチン投与によりがん局所にCD45RO陽性の活性化T細胞浸潤が認められる事を発見した(Noguchi他、Prostate,2007).このことによりテーラーメイドワクチンはがんに対する2次免疫応答を素早く活性化させてがん局所での免疫応答強化を引き出すことが強く示唆された。(5)インターフェロン抵抗性C型肝炎ウイルス感染者に対するテーラーメイドペプチドワクチンにおいて安全性と免疫反応性を確認し(Yutani他、Vaccine,2007)。
(まとめ):これまでのがん治療ペプチドワクチン開発の基盤的研究を一層充実しつつあるとともに、臨床研究に付随した免疫反応解析によりテーラーメイドワクチンが治療ワクチンとして推奨できる科学的根拠のひとつとしてのCD45陽性活性化リンパ球のがん局所浸潤を引き起こすことを明らかにした。

  • Research Products

    (25 results)

All 2007

All Journal Article (18 results) (of which Peer Reviewed: 17 results) Presentation (6 results) Patent(Industrial Property Rights) (1 results)

  • [Journal Article] Kinesin superfamily.protein-derived peptides with the ability toinduce glioma-reactive cytotoxic T lymphocytes in human leukocyte antigen-A24+ glioma patients.2007

    • Author(s)
      Harada M, Itoh K, et. al.
    • Journal Title

      Oncol Rep. 15

      Pages: 629-636

    • Peer Reviewed
  • [Journal Article] Identification of target antigens in specific immunotherapy for renal cell carcinoma.2007

    • Author(s)
      Komohara Y, Itoh K, et. al.
    • Journal Title

      J Urol. 177

      Pages: 1157-1162

    • Peer Reviewed
  • [Journal Article] Combination therapy of personalized peptide vaccination with a low-dose estramustine phosphate for metastatic hormone refractory prostate cancer patients:an analysis of prognostic factors in the treatment.2007

    • Author(s)
      Noguchi M, Itoh K, et. al.
    • Journal Title

      Oncol Res 16

      Pages: 341-349

    • Peer Reviewed
  • [Journal Article] Identification of new immunogenic peptides in conserved regions of hepatitis C virus(HCV)lb that can induce both cellular and humoral immunity in HCVlb+HLA-A24+patients.2007

    • Author(s)
      Takao Y, Itoh K, et. al.
    • Journal Title

      Hepatol Res 37

      Pages: 186-195

    • Peer Reviewed
  • [Journal Article] Immunological evaluation of neoadjuvant peptide vaccination before radical prostatectomy for patients with localized prostate cancer.2007

    • Author(s)
      Noguchi M, Itoh K, et. al.
    • Journal Title

      Prostate 67

      Pages: 933-942

    • Peer Reviewed
  • [Journal Article] Increased levels of IgG antibodies against peptides of prostate stem cell antigen in the plasma of pancreatic cancer patients.2007

    • Author(s)
      Tanaka M, Itoh K, et. al.
    • Journal Title

      Oncol Rep 18

      Pages: 161-166

    • Peer Reviewed
  • [Journal Article] Identification of SART3-derived peptides having the potential to induse cancer-reactive Cytotoxic T Lymphocytes from prostate cancer patients with HLA-A3 super type alleles.2007

    • Author(s)
      Minami T, Itoh K, et. al.
    • Journal Title

      Cancer Immunol Immunother. 56

      Pages: 689-698

    • Peer Reviewed
  • [Journal Article] Serum levels of IgG to the peptide of HCVlb vore at positions 35-44correlated with persistent infection,while levels of IgG to the peptide of NS5A at positions 2132-2140 correlated with better prognosis in HCV-infected patients.2007

    • Author(s)
      Takao Y, Itoh K, et. al.
    • Journal Title

      Med Microbiol Immunol. 196

      Pages: 157-164

    • Peer Reviewed
  • [Journal Article] A new epitope peptide derived from hepatitis C virus lb possessing the capacity to induce cytotoxic T-lymphocytes in HCVlb-infected patients with HLA-All,-A31and-A33.2007

    • Author(s)
      Natsueda S, Itoh K, et. al.
    • Journal Title

      Cancer Immunol Immunother. 56

      Pages: 1359-66

    • Peer Reviewed
  • [Journal Article] Expression of APOBC3G in kidney cells.2007

    • Author(s)
      Komohara Y, Itoh K, et. al.
    • Journal Title

      Tissue Antigens 69

      Pages: 95-98

    • Peer Reviewed
  • [Journal Article] Phase I clinical study of a personalized peptide vaccination for patients intected with hepatitis C virus(HCV)lb who failed to respond to interferon-based therapy.2007

    • Author(s)
      Yutani S, Itoh K, et. al.
    • Journal Title

      Vaccine 25

      Pages: 7429-35

    • Peer Reviewed
  • [Journal Article] HLA-G as a target molecule in specific immunotherapy against renalcell carcinoma.2007

    • Author(s)
      Komohara Y, Itoh K, et. al.
    • Journal Title

      Oncology Report 18

      Pages: 1463-1468

    • Peer Reviewed
  • [Journal Article] Immunological evaluation of personalized peptide vaccination with gemcitabine for pancreatic cancer.2007

    • Author(s)
      Yanagimoto Y, Itoh K, et. al.
    • Journal Title

      Can.Science 98

      Pages: 605-611

    • Peer Reviewed
  • [Journal Article] Immunological evaluation of personalized peptide vaccination in combination with a 5-fluorouracil derivativ(TS-1)for advanced gastric or colorectal carcinoma patients2007

    • Author(s)
      SatoY, Itoh K, et. al.
    • Journal Title

      Can.Science 98

      Pages: 1113-1119

    • Peer Reviewed
  • [Journal Article] Differential levels of human leukocyte antigen-class I,multidrug-resistancel and androgen receptor expressions in untreated prostate cancer cells:the robustness of prostate cancer.2007

    • Author(s)
      Homma S, Itoh K, et. al.
    • Journal Title

      Oncol Res 18

      Pages: 343-346

  • [Journal Article] New peptide vaccine candidates for epithelial cancer patients with HLA-A3supertype alleles.2007

    • Author(s)
      Matsueda S, Itoh K, et. al.
    • Journal Title

      J Immunother 30

      Pages: 274-281

    • Peer Reviewed
  • [Journal Article] New peptides of the polycomb group protein enhancer of zeste homolog 2with the potential to induce cancer-reactive cytotoxic T lymphocytes in humanleukocyte antigen-A2+prostate cancer patients.2007

    • Author(s)
      Itoh Y, Utoh K, et. al.
    • Journal Title

      Oncology Reports 18

      Pages: 1231-1237

    • Peer Reviewed
  • [Journal Article] Identification of Lck-derived peptides applicable to anti-cancer vaccine for patients with human leukocyte antigen-A3 supertype alleles.,2007

    • Author(s)
      Naito M, , Itoh K, et. al.
    • Journal Title

      British J Cancer 97

      Pages: 1648-1654

    • Peer Reviewed
  • [Presentation] Symposium 「Promotion of drug development in oncology throughinternational cooperation」2007

    • Author(s)
      Toyoshima S, Itoh K
    • Organizer
      第66回日本癌学会学術総会
    • Place of Presentation
      横浜
    • Year and Date
      20071003-05
  • [Presentation] Identification of EphB6 variant-derived epitope peptides recognized by cytotoxic T lymphocytes.,2007

    • Author(s)
      Jin M, Itoh K, et. al.
    • Organizer
      第66回日本癌学会学術総会
    • Place of Presentation
      横浜
    • Year and Date
      20071003-05
  • [Presentation] Identification of a peptide derived from HCV inducing cellular responses with various HLA class I-A alleles.2007

    • Author(s)
      Shichijo S, Itoh K, et. al.
    • Organizer
      第66回目本癌学会学術総会
    • Place of Presentation
      横浜
    • Year and Date
      20071003-05
  • [Presentation] Elimination of cancer stem cells in drug-resistance by Notch and Numb-peptide activated T cells.2007

    • Author(s)
      Mine T, Itoh K, et. al.
    • Organizer
      第66回日本癌学会学術総会
    • Place of Presentation
      横浜
    • Year and Date
      20071003-05
  • [Presentation] Phase I clinical trial of pan-HLA type personalized peptide vaccine for advanced cancer patients.2007

    • Author(s)
      Yamada A, Itoh K, et. al.
    • Organizer
      第66回日本癌学会学術総会
    • Place of Presentation
      横浜
    • Year and Date
      20071003-05
  • [Presentation] テーラーメイド癌ペプチドワクチン開発の現状と展望2007

    • Author(s)
      伊東恭悟他
    • Organizer
      第27回日本医学会総会
    • Place of Presentation
      大阪
    • Year and Date
      20070406-08
  • [Patent(Industrial Property Rights)] HLA-A24分子結合性KIF由来ペプチド2007

    • Inventor(s)
      伊東恭悟、原田守、山中龍也
    • Industrial Property Number
      PCT/JP2007/065273
    • Filing Date
      2007-08-03

URL: 

Published: 2010-02-04   Modified: 2016-04-21  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi